Last reviewed · How we verify
CEP-701
At a glance
| Generic name | CEP-701 |
|---|---|
| Also known as | lestaurtinib |
| Sponsor | Cephalon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (PHASE3)
- N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma (PHASE1)
- Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML) (PHASE2)
- Lestaurtinib With or Without Chemotherapy Agents in Samples From Young Patients With Leukemia
- Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis (PHASE2)
- CEP-701 (Lestaurtinib) in Myelofibrosis (PHASE1, PHASE2)
- Study of CEP-701 in Treatment of Prostate Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CEP-701 CI brief — competitive landscape report
- CEP-701 updates RSS · CI watch RSS
- Cephalon portfolio CI